ArticleEuropean radiology2007
Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions.
Article in European radiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The GREENBEAN checklist for reporting studies evaluating the effectiveness of EEG-based biomarkers.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2025Review
- Biomarker Discovery and Validation: Statistical Considerations.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
- Multiparametric MR for non-invasive evaluation of tumour tissue histological characteristics after radionuclide therapy.NMR in biomedicine · 2019Article
- Hepatic neuroendocrine tumour: Apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival.European radiology · 2018Article
- Early changes in the apparent diffusion coefficient and MMP-9 expression of a cervical carcinoma U14 allograft model following irradiation.Oncology letters · 2017Article
- Strategies for modern biomarker and drug development in oncology.Journal of hematology & oncology · 2014Review
- Correlation of ADC value with pathologic indexes in colorectal tumor homografts in Balb/c mouse.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Article
- Article
- Functional and molecular image guidance in radiotherapy treatment planning optimization.Seminars in radiation oncology · 2011Review
- Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.Neoplasia (New York, N.Y.) · 2009Article
- Imaging biomarkers: from research to patient care--a shift in view.European journal of nuclear medicine and molecular imaging · 2007Review
- Feasibility of 4D perfusion CT imaging for the assessment of liver treatment response following SBRT and sorafenib.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surrogate markers and biomarkers based on imaging readouts providing predictive information on clinical outcome are of increasing importance in the preclinical and clinical evaluation of novel therapies. They are primarily used in studies designed to establish evidence that the therapeutic principle is valid in a representative patient population or in an individual. A critical step in the development of (imaging) surrogates is validation: correlation with established clinical endpoints must be demonstrated. Biomarkers must not fulfill such stringent validation criteria; however, they should provide insight into mechanistic aspects of the therapeutic intervention (proof-of-mechanism) or document therapy efficacy with prognostic quality with regard to the long-term clinical outcome (proof of concept). Currently used imaging biomarkers provide structural, physiological and metabolic information. Novel imaging approaches annotate structure with molecular signatures that are tightly linked to the pathophysiology or to the therapeutic principle. These cellular and molecular imaging methods yield information on drug biodistribution, receptor expression and occupancy, and/or intra- and intercellular signaling. The design of novel target-specific imaging probes is closely related to the development of the therapeutic agents and should be considered early in the discovery phase. Significant technical and regulatory hurdles have to be overcome to foster the use of imaging biomarkers for clinical drug evaluation.
Indexed as
Identifiers
17340100What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.